Abstract

Background: MACBETH trial aimed at evaluating the efficacy of a 4 months-induction with mFOLFOXIRI plus cet in RAS/BRAF wt mCRC patients (pts), followed by two different maintenance strategies: continuing cet or switching to bev. Although the primary endpoint, 10 months-Progression Free Rate, was not met in any treatment arm, the induction treatment was very active and the safety profile was acceptable. Methods: Unresectable and untreated mCRC pts aged between 18 and 75 ys were eligible if their tumors were RAS/BRAF wt at central screening. Pts were randomized to receive up to 8 cycles of mFOLFOXIRI + cet (cet 500 mg/sqm, iri 130 mg/sqm, oxa 85 mg/sqm, I-LV 200 mg/sqm, 5FU 2400 mg/sqm in 48h q2w), followed by cet (arm A) or bev (arm B) until progression (PD). Results: Between Nov 2011 and Feb 2015, 323 pts from 21 Italian centers were screened and 116 pts were included in the modified intention to treat (mITT) population (arm A/B N = 59/57). Response rate was 72% (arm A/B 68%/75%) in the mITT population and 76% in 109 evaluable pts. Early response rate was 74% (arm A/B 74%/74%), and median deepness of response was 53% (arm A/B 49%/56%). Resection rate was 38% (arm A/B 46%/30%) in the mITT population and 65% (arm A/B 71%/58%) in the liver-only subgroup (N = 52, arm A/B 28/24). One-third of pts with liver-only disease who achieved resection underwent re-resection with radical intent after PD. At a median follow-up of 25.5 months, 100 pts (arm A/B 48/52) progressed. Median PFS in arm A and B was 11.2 and 9.3 months, respectively (HR: 0.78 [0.52-1.18). Among patients who received at least one cycle of maintenance (arm A/B N = 36/41) median PFS was 14.0 and 10.7 months (HR: 0.63 [0.37-1.08]), and median PFS from the beginning of maintenance was 8.6 and 5.6 months (HR: 0.69 [0.40-1.17]). Conclusions: mFOLFOXIRI + cet demonstrated remarkable activity, leading to high resection rate. Re-resections were achievable after PD in a considerable subgroup of pts with liver-only disease, supporting the long-term impact of active upfront regimens. Continuing cet as maintenance until PD seems to positively affect PFS. OS results will be presented.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call